Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.

Article Details

Citation
Copy to clipboard

Jones RN, Fritsche TR, Sader HS, Ross JE

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.

Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6.

PubMed ID
16801451 [ View in PubMed
]
Abstract

Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

DrugBank Data that Cites this Article

Drugs